NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00002-5337-62 | 00002-5337 | Abemaciclib | Verzenio | 150.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Feb 15, 2025 | In Use | |
55111-0172-30 | 55111-0172 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 28, 2007 | In Use | |
53217-0231-90 | 53217-0231 | Dexamethasone | Dexamethasone | 0.75 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 3, 1975 | In Use | |
54868-1119-01 | 54868-1119 | Prednisone | Prednisone | 1.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 5, 2004 | In Use | |
50383-0040-04 | 50383-0040 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 5.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 26, 2003 | In Use | |
50742-0497-53 | 50742-0497 | gemcitabine | GEMCITABINE | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 1, 2023 | In Use | |
54868-4030-00 | 54868-4030 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Sep 18, 2000 | In Use | ||
70771-1348-01 | 70771-1348 | methylprednisolone | methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 1, 2018 | In Use | |
83090-0009-10 | 83090-0009 | Arsenic trioxide | ARSENIC TRIOXIDE | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Nov 9, 2023 | In Use | |
63187-0065-10 | 63187-0065 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 1, 2014 | In Use | |
00093-7355-56 | 00093-7355 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Dec 15, 2006 | In Use | |
54868-4287-00 | 54868-4287 | Tamoxifen Citrate | Tamoxifen Citrate | 20.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan 17, 2005 | In Use | ||
72205-0030-92 | 72205-0030 | Abiraterone acetate | Abiraterone | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Jul 10, 2019 | In Use | |
70771-1692-01 | 70771-1692 | Pemetrexed disodium | Pemetrexed | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 26, 2022 | In Use | |
73555-0502-00 | 73555-0502 | Revumenib | Revuforj | 160.0 mg/1 | Chemotherapy | Enzyme Inhibitor | KMT2A | Oral | Nov 15, 2024 | In Use | |
00378-4791-06 | 00378-4791 | Fluorouracil | Fluorouracil | 5.0 mg/g | Chemotherapy | Antimetabolite | Pyrimidine Analog | Topical | Sep 19, 2013 | In Use | |
54868-5636-02 | 54868-5636 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jun 30, 2006 | In Use | |
68727-0950-02 | 68727-0950 | Zanidatamab-hrii | ZIIHERA | 50.0 mg/mL | Immunotherapy | Bispecific Antibody | HER2 | Intravenous | Nov 20, 2024 | In Use | |
47335-0930-21 | 47335-0930 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
13668-0592-86 | 13668-0592 | APREPITANT | APREPITANT | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct 21, 2020 | In Use | |
70518-2982-00 | 70518-2982 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 7, 2021 | In Use | |
80425-0193-01 | 80425-0193 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 20, 2024 | In Use | |
55111-0156-30 | 55111-0156 | Ondansetron Hydrochloride | ONDANSETRON | 24.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 26, 2006 | In Use | |
50242-0260-86 | 50242-0260 | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf | Phesgo | 20000.0 U/10mL, 600.0 mg/10mL, 600.0 mg/10mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | May 3, 2021 | In Use | |
63323-0750-10 | 63323-0750 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jun 11, 2010 | In Use |
Found 11765 results — Export these results